Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 3
2016 1
2017 2
2018 4
2019 1
2020 3
2021 3
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators. Weir MR, et al. N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21. N Engl J Med. 2015. PMID: 25415805 Free article. Clinical Trial.
We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS: Patients with chronic kidney disease who were receiving RAAS inhibitors and who had serum potassium lev …
We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial. METHODS: Pa …
Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors.
Kloner RA, Gross C, Yuan J, Conrad A, Pergola PE. Kloner RA, et al. J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):524-531. doi: 10.1177/1074248418788334. Epub 2018 Aug 14. J Cardiovasc Pharmacol Ther. 2018. PMID: 30103622 Free PMC article. Clinical Trial.
INTRODUCTION: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of the use of renin-angiotensin-aldosterone system inhibitors (RAASi). ...CONCLUSIONS: Patiromer was effective and generally well-t …
INTRODUCTION: Hyperkalemia (potassium >5.0 mEq/L) affects heart failure patients with renal disease regardless of th …
Patiromer: A Review in Hyperkalaemia.
Blair HA. Blair HA. Clin Drug Investig. 2018 Aug;38(8):785-794. doi: 10.1007/s40261-018-0675-8. Clin Drug Investig. 2018. PMID: 30030701 Review.
In clinical trials, patiromer reduced serum potassium levels and the risk of recurrent hyperkalaemia in patients with chronic kidney disease (CKD) and/or diabetic nephropathy with or without heart failure (HF), allowing the majority of patien …
In clinical trials, patiromer reduced serum potassium levels and the risk of recurrent hyperkalaemia in patients with c …
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.
Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL. Weir MR, et al. Am J Med. 2018 May;131(5):555-564.e3. doi: 10.1016/j.amjmed.2017.11.011. Epub 2017 Nov 26. Am J Med. 2018. PMID: 29180023 Free article. Clinical Trial.
We studied the efficacy and safety of patiromer in a prespecified subgroup of patients aged 65 years from OPAL-HK. METHODS: Chronic kidney disease patients with mild or moderate-to-severe hyperkalemia received patiromer, ini …
We studied the efficacy and safety of patiromer in a prespecified subgroup of patients aged 65 years from OPAL-HK. METHODS: Ch …
Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.
Palmer BF. Palmer BF. Mayo Clin Proc. 2020 Feb;95(2):339-354. doi: 10.1016/j.mayocp.2019.05.019. Epub 2019 Oct 23. Mayo Clin Proc. 2020. PMID: 31668450 Free article. Review.
Hyperkalemia is a potentially life-threatening complication of chronic kidney disease (CKD). ...There may also be a role for these agents in preventing hyperkalemia in patients receiving hemodialysis. Thus, K(+)-binding agents may allow …
Hyperkalemia is a potentially life-threatening complication of chronic kidney disease (CKD). ...There may also be a rol …
Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.
Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Pitt B, et al. Eur J Heart Fail. 2015 Oct;17(10):1057-65. doi: 10.1002/ejhf.402. Epub 2015 Oct 12. Eur J Heart Fail. 2015. PMID: 26459796 Free PMC article.
METHODS AND RESULTS: Chronic kidney disease (CKD) patients on renin-angiotensin-aldosterone system inhibitors (RAASi) with serum K(+) levels 5.1 mEq/L to <6.5 mEq/L (n = 243) received patiromer (4.2 g or 8.4 g BID initially) for 4 week …
METHODS AND RESULTS: Chronic kidney disease (CKD) patients on renin-angiotensin-aldosterone system inhibitors (R …
Hyperkalaemia in Heart Failure.
Ismail U, Sidhu K, Zieroth S. Ismail U, et al. Card Fail Rev. 2021 May 12;7:e10. doi: 10.15420/cfr.2020.29. eCollection 2021 Mar. Card Fail Rev. 2021. PMID: 34094588 Free PMC article. Review.
Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin-angiotensin-aldosterone system (RAAS) inhibitors and angiotensin-neprilysin inhibitors being the cornerstone of medical therapy …
Hyperkalaemia has become an increasingly prevalent finding in patients with heart failure (HF), especially with renin-angioten …
Hyperkalemia with RAAS inhibition: Mechanism, clinical significance, and management.
Hundemer GL, Sood MM. Hundemer GL, et al. Pharmacol Res. 2021 Oct;172:105835. doi: 10.1016/j.phrs.2021.105835. Epub 2021 Aug 23. Pharmacol Res. 2021. PMID: 34438065 Review.
Renin-angiotensin-aldosterone system (RAAS) inhibitors are evidence-based treatments for a number of conditions including hypertension, diabetes mellitus, chronic kidney disease, and congestive heart failure. ...Yet discontinuation of RAAS in …
Renin-angiotensin-aldosterone system (RAAS) inhibitors are evidence-based treatments for a number of conditions including hype …
Patiromer: The First Potassium Binder Approved in Over 50 Years.
Vu BN, De Castro AM, Shottland D, Frishman WH, Cheng-Lai A. Vu BN, et al. Cardiol Rev. 2016 Nov/Dec;24(6):316-323. doi: 10.1097/CRD.0000000000000123. Cardiol Rev. 2016. PMID: 27548687 Review.
For over 50 years, there have been limited options for the management of hyperkalemia, especially among patients with chronic kidney disease (CKD), diabetic nephropathy, hypertension, and heart failure, who were receiving concomitant renin-angio …
For over 50 years, there have been limited options for the management of hyperkalemia, especially among patients with chronic …
Revisiting RAAS blockade in CKD with newer potassium-binding drugs.
Georgianos PI, Agarwal R. Georgianos PI, et al. Kidney Int. 2018 Feb;93(2):325-334. doi: 10.1016/j.kint.2017.08.038. Epub 2017 Dec 21. Kidney Int. 2018. PMID: 29276100 Free PMC article. Review.
Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agents blocking the renin angiotensin aldosterone system (RAAS) as first-line antihypertensive therapy based on randomized trials demonst …
Among patients with proteinuric chronic kidney disease (CKD), current guideline recommendations mandate the use of agen …
15 results